60,000 名科学家呼吁停止大规模疫苗接种

2021 年 12 月 5 日- 11:38 pm 法国每日新闻

科学界公开反对当局的健康政策：Great Barrington（美国）反对大规模注射 mRNA 的声明已收集到 870.000 个签名。

在法兰西共和国总统于 12 月 6 日星期一召开新的国防委员会会议以对抗 Covid-19 流行病的蔓延之际，越来越多的声音被提出来反对当局完全疯狂的卫生政策，该政策旨在为越来越多的人接种疫苗。接种第三剂疫苗后，将面临停用健康通行证的处罚！现在有为 5 至 11 岁儿童接种疫苗的问题。根据我们在这里报道的许多医生和研究人员的说法，这是一个非常严重的决定。

严重的副作用

使用仍在实验中的信使 RNA 疫苗进行大规模疫苗接种长期以来一直困扰着科学界。截至2020年10月4日，三位高水平科学家，哈佛大学医学教授、生物统计学家和流行病学家Martin Kulldorff教授，专门从事传染病暴发的检测和监测以及疫苗安全性评估。Sunetra Gupta 博士，牛津大学教授，专攻免疫学、疫苗开发和传染病数学建模的流行病学家。还有杰伊·巴塔查里亚博士斯坦福大学医学院教授、内科医生、流行病学家、健康经济学家和专门研究传染病和弱势群体的公共卫生政策专家，在所谓的“大巴灵顿宣言”中推荐了一种替代 Covid-19 的方法。因为他们非常关注大规模疫苗接种对人群的副作用。

他们提倡什么？“重点”保护。也就是说，尽可能保护老年人、体弱者、体弱者，让其他人正常生活，直到社会达到集体免疫。然而，通过 mRNA 进行大规模疫苗接种使得这种集体免疫成为不可能。

最初的共同签署人之一是奥克兰大学的流行病学家和生物统计学家 Simon Thornley 博士。此后，60,000 名医生和科学家签署了《伟大的巴灵顿宣言》，并在世界范围内变得越来越广为人知。迄今为止，一份请愿书已收集到 870,000 个支持签名。

伟大的巴灵顿宣言

“伟大的巴灵顿宣言——作为传染病流行病学家和公共卫生科学家，我们对现行 COVID-19 政策对身心健康的破坏性影响表示严重关切，并推荐一种我们称之为重点保护的方法。

我们来自左翼和右翼，来自世界各地，致力于保护人民。当前的封锁政策正在对短期和长期公共卫生产生破坏性影响。结果（仅举几例）包括儿童疫苗接种率降低、心血管疾病结果恶化、癌症筛查减少和心理健康恶化——导致未来几年更高的超额死亡率，工人阶级和年轻的社会成员承受着最沉重的负担. 让学生辍学是一种严重的不公平现象。

在疫苗可用之前保持这些措施到位将造成无法弥补的损害，弱势群体受到的伤害不成比例。

幸运的是，我们对病毒的了解正在增长。我们知道，老年人和体弱者死于 COVID-19 的风险比年轻人高一千多倍。事实上，对于儿童来说，COVID-19 的危险性低于包括流感在内的许多其他危害。

随着人群免疫力的增强，包括弱势群体在内的所有人感染的风险都会下降。我们知道所有人群最终都会达到群体免疫——即新感染率稳定的点——这可以通过（但不依赖于）疫苗来辅助。因此，我们的目标应该是尽量减少死亡率和社会危害，直到我们达到群体免疫。

平衡获得群体免疫的风险和收益的最富有同情心的方法是让那些死亡风险最低的人过上正常的生活，通过自然感染建立对病毒的免疫力，同时更好地保护那些最高的人风险。我们称之为重点保护。

采取措施保护弱势群体应该是公共卫生应对 COVID-19 的中心目标。例如，疗养院应使用具有获得性免疫力的工作人员，并对其他工作人员和所有访客进行频繁的检测。应尽量减少人员轮换。住在家里的退休人员应该将杂货和其他必需品送到家中。如果可能，他们应该在外面而不是在里面与家人会面。可以实施全面而详细的措施清单，包括针对多代家庭的方法，并且完全在公共卫生专业人员的范围和能力范围内。

那些不脆弱的人应立即被允许恢复正常生活。每个人都应采取简单的卫生措施，例如洗手和生病时待在家里，以降低群体免疫阈值。学校和大学应开放面对面教学。应恢复体育等课外活动。年轻的低风险成年人应该正常工作，而不是在家工作。餐馆和其他企业应该开放。艺术、音乐、体育和其他文化活动应恢复。风险更大的人可以根据自己的意愿参与，而整个社会则享有建立群体免疫力的人给予弱势群体的保护。”

Covid-19（和疫苗）对性器官和生育能力的风险

2022 年 3 月 21 日- 晚上 10:00 由Emilien Lacombe

采访 Jean-Marc Sabatier 博士*。

SARS-CoV-2 会感染生殖器官吗？

在男性中，SARS-CoV-2 可以攻击睾丸、阴茎和前列腺。在女性中，病毒可以攻击子宫（子宫内膜）和卵巢。为什么这些攻击是可能的？因为 SARS-CoV-2 识别细胞受体 ACE2（血管紧张素转换酶 2），它作为一个结合位点，使其能够感染细胞；ACE2受体非常存在于男性和女性生殖器官的细胞中，这使得它们非常容易感染病毒。值得注意的是，除了生殖器官，包括性腺（睾丸和卵巢）之外，ACE2 受体也存在于身体的许多其他器官和组织（因此成为病毒的目标），例如心脏、肺、肾、肝、胰、脾、血管系统（血管）、皮肤、脑、肠、肾上腺等

病毒如何影响这些器官？

通过与靶细胞的 ACE2 受体结合，SARS-CoV-2 过度激活了对人体功能至关重要的激素和生理系统：肾素-血管紧张素系统或 RAS（ACE2 受体是其中不可或缺的一部分） ) 其中存在“局部”变体/适应 RAS 的过度激活导致其“有害”受体 AT1R（血管紧张素-2 受体 1 型）过度激活，主要引起血管收缩/高血压、炎症、纤维化、氧化应激和下降一氧化氮（对我们的性器官有害）。在人体（以及一般的哺乳动物）中，RAS 控制着肾、肺、心血管自主神经功能、先天免疫以及肠道甚至口腔微生物群。

男人呢？

在男性生殖系统中，RAS 的成分（配体/激素和各种酶受体）存在于睾丸、精子和精液中。归因于这种“局部”RAS的一些功能是维持精浆电解质、调节类固醇生成（类固醇激素的合成，包括雄性雄激素）和精子发生（睾丸中产生精子的过程）、附睾收缩力和精子功能。

因此，当感染男性时，SARS-CoV-2 可能会通过其对男性生殖系统中 RAS 的作用来改变雄激素（包括睾酮）和精子的产生。这些不利影响可能会影响男性生育能力，因为迄今为止已广泛证明 RAS 在生育力或不育症（男性和女性）中的重要性。因此，血管紧张素 2 和 AT1R 受体是“局部”RAS 的关键要素。Angiotensin-2 参与睾酮产生的下调和睾丸生长的调节，而 AT1R 受体抑制精子发生和睾酮的产生。

据报道，在一些感染 SARS-CoV-2 的人中，阴茎和睾丸的大小会减小，这应该是 RAS 功能障碍引起的这些性功能障碍的“可见”影响。

女人呢？

女性有卵巢 RAS（称为 OVRAS），在卵巢生理学和相关卵巢疾病中起关键作用。卵巢 RAS 对卵泡发育/闭锁、排卵和类固醇激素分泌有重大影响，因此是正常生殖所必需的。事实上，这种 RAS 的作用者存在于卵泡、卵泡膜和颗粒的排卵前细胞以及颗粒-叶黄素的排卵后细胞中。它还参与调节类固醇生成（类固醇激素的合成，包括女性雌激素）。

月经失调

因此，SARS-CoV-2 可能诱发的卵巢 RAS 功能障碍可能会影响卵母细胞的成熟和排卵（月经周期的改变），并导致不孕症、卵巢癌、多囊卵巢综合征等疾病或病症。自身免疫抗体的存在直接针对 AT1R 受体可导致不育。

在女性中，可以观察到或多或少的显着和致残的月经周期紊乱（除了其他潜在的 Covid-19 病理）。月经对应于通过阴道的生物流体的周期性流动，包括血液、阴道分泌物和子宫内膜细胞（子宫壁）。月经对应于排出在月经周期中形成的子宫粘膜表层（子宫内膜）以容纳可能的受精卵。在没有受精的情况下，子宫内膜表面（高度血管化）然后以出血的形式通过阴道排出。SARS-CoV-2 病毒（通过其刺突蛋白）与靶细胞的 ACE2 受体结合。子宫内膜和血管系统由上皮细胞和内皮细胞组成，它们像卵巢或睾丸一样表达刺突蛋白识别的 ECA2 受体。这表明刺突蛋白（来自 SARS-CoV-2 或疫苗）可以直接作用于子宫内膜和相关血管。

为什么我们会出现出血性疾病？

SARS-CoV-2 - 通过刺突蛋白 - 导致凝血障碍，包括血小板减少症（帮助血液凝结的血小板数量减少）。

因此，SARS-CoV-2 或疫苗刺突蛋白直接导致某些 SARS-CoV-2 病毒感染或接种疫苗后的人有时会出现凝血和月经紊乱。关于与疫苗相关的月经失调，我必须提到法国国家药品安全局(ANSM) 的相反意见，该机构在 2021 年 12 月 21 日发布的 Covid-19 疫苗监测状态更新中写道：“迄今为止，现有数据不允许我们确定疫苗与这些月经周期紊乱的发生之间的直接联系。这些事件仍处于监视之下。

然而，许多女性发现事实恰恰相反……

可以做些什么来对抗这些疾病？

适当的维生素 D 补充剂（40-60 ng 骨化二醇/mL 血液）对于预防、治疗或减轻这些生殖系统疾病是可取的，因为它通过抑制 RAS 的“有害”过度激活来发挥作用（除其他外）关于肾素生产）。值得注意的是，某些病变可能几乎是不可逆的，例如器官或组织纤维化。

此外，纳米颗粒的潜在有害影响（参见某些疫苗组合物的脂质纳米颗粒）：https ://lnkd.in/gVqtwH7d

* Jean-Marc Sabatier 是 CNRS 的研究主任，拥有细胞生物学和微生物学博士学位，隶属于艾克斯马赛大学神经生理病理学研究所 (INP)。

CDC表示，Covid疫苗与心脏问题相关的证据越来越充分

这种被称为心肌炎的情况通常很轻微，但仍有少数患者住院。

2021 年 6 月 11 日凌晨 3:57 CST

美国疾病控制和预防中心周四表示，在接种 Covid-19 疫苗后，报告的一种心脏炎症病例数量高于往常，尤其是在第二剂 mRNA 疫苗接种后的年轻男性中。

CDC 免疫安全办公室副主任 Tom Shimabukuro 博士在向食品和药物管理局咨询小组介绍时说，总体而言，已确认 226 例 30 岁以下人群接种疫苗后发生心肌炎或心包炎。然而，需要进一步调查以确认疫苗接种是否是心脏问题的原因。

通常，预计该年龄组的病例少于 100 例。

全面覆盖冠状病毒爆发

青少年和 20 岁出头的人在 Covid-19 疫苗接种后向 CDC 安全监测系统报告的心肌炎病例中占了一半以上，尽管他们只占接种疫苗的人的一小部分。

“我们显然存在不平衡，”Shimabukuro 说。

截至 5 月底，绝大多数病例在去医院就诊后被送回家。目前尚不清楚有多少患者入院，或者例如在急诊室就诊后出院。15 名患者仍在住院，其中 3 名在重症监护室。ICU 中的两名患者还有其他健康问题。

CDC 掌握了 220 例患者康复的信息；在这些病例中，超过 80% 是患者自行好转。

演讲结束后，波士顿塔夫茨儿童医院儿科传染病科主任科迪•迈斯纳博士说：“很难否认，心肌炎似乎正在发生一些事件。”

心肌炎是涉及心肌炎症的病症。症状可能包括发烧和疲劳，以及呼吸急促和一种非常特殊的胸痛。患者倾向于说，当他们身体前倾时，他们的胸部会更痛。当他们向后倾斜时，疼痛往往会减轻。

需要时，治疗可能涉及抗炎药，例如布洛芬，在某些情况下，还可能涉及一种称为 IVIG 的静脉注射药物。

一般来说，患有心肌炎的儿童会在心脏病专家那里随访大约六个月，以确保没有其他重大问题。大多数病例通常是轻微的并且会自行消失。

疫苗安全专家一直在寻找任何新疫苗后可能出现的一系列副作用。Shimabukuro 说，尽管年轻人中报告的心肌炎病例数量有所增加，但尚未发现重大危险信号。

尽管如此，高于正常水平的发病率仍值得进一步审查。CDC 将于 6 月 18 日召开免疫实践咨询委员会会议，进一步研究证据并评估接种疫苗后患心肌炎的风险。

在建立明确的联系之前，卫生官员压倒性地建议所有 12 岁及以上的人接种 Covid-19 疫苗。

Heart attack risk

Safety

Myocarditis

COVID-19 and heart issues

Vaccine protection for heart problems

Summary

zoranm/Getty Images

As with most vaccines, you may experience some side effects with the COVID-19 vaccine. The most common side effect is soreness or redness at the site of the injection. You may have also heard about heart-related side effects and wondered if this is a cause for concern.

While there’s no credible evidence that the COVID-19 vaccine increases the risk of heart attack, it can lead to heart inflammation in some people. However, this effect is typically mild and goes away with treatment.

It’s also important to keep in mind that, according to researchTrusted Source, the rate of heart inflammation (myocarditis) from the vaccine seems to occur at a much lower rate than heart inflammation caused by COVID-19 infection.

Keep reading to learn more about whether the vaccine is safe for people with heart conditions and whether the COVID-19 vaccine increases your risk of a heart attack.

Does the COVID-19 vaccine increase the risk of a heart attack?

There’s not currently any credible evidence that the COVID-19 vaccine increases your risk of a heart attack.

These concerns initially came about due to an abstractTrusted Source in the journal Circulation, which is published by the American Heart Association.

This abstract presented a short summary of preliminary research that had not yet been peer reviewed by other scientists.

What did the abstract say?

Researchers used something called the Protein Unstable Lesion Signature (PULS) Cardiac Test in 566 people visiting a cardiac clinic. All of these individuals had recently received the second dose of one of the mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna).

The PULS Cardiac Test claims to predict heart attack risk over a 5-year period by measuring nine different markers in a blood sample. After the marker levels are determined, a score is generated. A higher PULS score may indicate an increased heart attack risk.

In the individuals tested, three of the nine markers had increased following vaccination. These markers were associated with inflammation. The increase boosted the PULS score by a predicted 11 percent compared to pre-vaccination levels.

What happened next?

Following the publication of this abstract, some outlets reported that, due to the increase in PULS score, the mRNA COVID-19 vaccines increased the risk of heart attack.

The American Heart Association released an expression of concernTrusted Source about the abstract shortly afterward. In it, they noted that the abstract may not be reliable due to several errors, no statistical analysis, and a lack of data directly linking the findings to heart attack risk.

In response to these concerns, the authors of the abstract revisedTrusted Source it to more clearly state that their findings are observational and have not been tested for significance in further experiments.

Vaccination usually raises inflammation levels temporarily as your body generates a response to the vaccine. Because of this, it’s natural to see increases in some markers of inflammation. However, these cannot currently be directly tied to heart attack risk.

SUMMARY

There’s currently no evidence that the COVID-19 vaccine increases your heart attack risk.

Some observations have found an increase in certain markers of inflammation following vaccination. However, it remains to be determined how exactly these findings may affect heart attack risk, if at all.

Is the vaccine safe for people with heart conditions?

The COVID-19 vaccine is safe for people with heart conditions.

Clinical trials have been done to determine the safety and effectiveness of each of the vaccines in use in the United States. These trials included both healthy individuals and those with various underlying health conditions, including heart conditions.

In fact, vaccination is actually vital if you have a heart condition. This is because individuals with heart conditions are at an increased risk of experiencing serious illness if they get COVID-19.

According to the Centers for Disease Control and Prevention (CDC)Trusted Source, the only people who shouldn’t receive a COVID-19 vaccine are individuals who:

have experienced a severe allergic reaction, called anaphylaxis, to a previous dose of the COVID-19 vaccine or to one of its ingredients

have a known allergy to an ingredient in the COVID-19 vaccine

developed thrombosis with thrombocytopenia syndrome (TTS), a severe blood clotting condition, following vaccination with the Johnson and Johnson COVID-19 vaccine (these individuals should choose an mRNA vaccine instead)

What’s known about the link between myocarditis and the vaccine?

Both myocarditis and pericarditis have been reported after receiving the COVID-19 vaccine. Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the sac surrounding the heart.

According to the CDCTrusted Source, myocarditis and pericarditis are more likely to happen:

in adolescent or young adult males

after vaccination with an mRNA COVID-19 vaccine such as Pfizer-BioNTech or Moderna

following the second vaccine dose

within a week of vaccination

A studyTrusted Source published in the journal Circulation looked at 139 adolescents and young adults with suspected myocarditis after COVID-19 vaccination. It found that most cases of myocarditis were mild and went away quickly with treatment.

Overall, this side effect is rare. A cohort studyTrusted Source published in the British Medical Journal estimated that only 1.7 out of 100,000 people go on to develop myocarditis or pericarditis within 28 days of getting their COVID-19 vaccine.

You actually have a greater risk of developing myocarditis from COVID-19 than from the vaccine.

A studyTrusted Source in the journal Nature Medicine estimated that 40 myocarditis events per 1 million people happen following a positive COVID-19 test, compared with 10 per 1 million people following the second dose of the Moderna vaccine.

Can COVID-19 cause heart-related issues?

COVID-19 doesn’t just affect the lungs and respiratory tract. Contracting the novel coronavirus can also lead to a variety of heart- and blood-related issues as well, such as:

damage to the heart muscle

arrhythmia

blood clots, which can cause complications like heart attack, stroke, pulmonary embolism, and deep vein thrombosis

heart failure

cardiomyopathy

myocarditis

pericarditis

A 2021 Cochrane review examined 220 studies that reported heart-related issues due to COVID-19. It found that the most common heart issues associated with COVID-19 were arrhythmias, blood clots, and heart failure.

Other effects of COVID-19

COVID-19 can affect many different organs and tissues in your body. For example, COVID-19 can also affect your:

lungs, potentially leading to pneumonia, lung damage, and acute respiratory distress syndrome (ARDS)

nervous system, causing headache, loss of smell and taste, dizziness, nerve pain, and seizures

kidneys, causing kidney damage

liver, leading to liver damage

pancreas, causing pancreatic damage

digestive tract, leading to symptoms like nausea, vomiting, diarrhea, and abdominal pain

eyes, causing conjunctivitis

skin, leading to rashes or “COVID toes”

Some people may also experience lingering symptoms in the weeks and months after recovering from COVID-19. This is often referred to as long COVID and may include, but isn’t limited to:

shortness of breath

fatigue

brain fog

Long COVID isn’t uncommon. A systematic review and meta-analysisTrusted Source published in Scientific Reports assessed 15 studies on the long-term effects of COVID-19, including a total of 47,910 people. Researchers estimated that 80 percent of these people had 1 or more long-term symptoms.

Should you get the vaccine if you have heart problems?

Older adults and people with certain health conditions are at an increased risk of becoming seriously ill due to COVID-19. According to the CDCTrusted Source, the following heart problems increase your risk of severe disease from COVID-19:

coronary artery disease

heart failure

cardiomyopathy

high blood pressure

A study published in Heart reviewed 51 studies, including 48,317 people with COVID-19. It found that cardiovascular disease, high blood pressure, and diabetes were associated with a higher risk of severe disease or death due to COVID-19 across all age groups.

As such, the American Heart Association has put out a statementTrusted Source urging all individuals with any cardiovascular risk factors to receive their COVID-19 vaccine. This also includes people who’ve previously experienced a heart attack or stroke.

Getting vaccinated for COVID-19 can protect you from becoming sick with COVID-19. Should you contract the virus, it can help lower your risk of serious illness, hospitalization, or death.

The bottom line

There’s not any reliable evidence that the COVID-19 vaccine can cause heart attacks. This idea is based on a misinterpretation of preliminary research findings. Overall, further research into this topic is needed.

It’s true that in rare cases, the COVID-19 vaccine can lead to myocarditis and pericarditis. However, the risk of these conditions is actually higher after contracting COVID-19 than after receiving the COVID-19 vaccine.

COVID-19 itself can cause potentially serious heart-related issues. Additionally, individuals with heart conditions are at an increased risk of serious illness or death due to COVID-19. That’s why it’s important to get vaccinated if you have a heart condition.

The COVID-19 vaccine is safe for people with heart conditions. If you have concerns about receiving the COVID-19 vaccine, talk with your doctor or cardiologist. They can help answer any questions you have about the vaccine and your heart condition.

Heart Inflammation Risk After COVID-19 Vaccine Is Real, But Rare

 Share on PinterestSeveral studies show that adolescents and young males have a higher risk of myocarditis after COVID-19 vaccination, but this condition is more common after coronavirus infection. Luza studios / Getty Images

•Several studies have found that the risk of heart inflammation after mRNA COVID-19 vaccination is real, but it’s fairly mild and extremely rare.

•Most studies show that adolescents and young males have a higher risk, particularly after the second dose.

•The risk of myocarditis after coronavirus infection has been found to be higher than after vaccination.

The risk of heart inflammation after mRNA COVID-19 vaccination is a rare and fairly mild event, research shows.

Adolescents and young males have a higher risk, particularly after the second dose. One study also found that the risk was lower after a booster dose.

Myocarditis can also occur after coronavirus infection, with rates higher than after COVID-19 vaccination.

Here is a summary of several recent studies.

Nordic study finds higher risk in young males

A study of over 23 million people aged 12 years or older in four Nordic countries examined the risk of myocarditis after receiving an mRNA COVID-19 vaccine.

Researchers found that the risk of heart inflammation was highest in males aged 16 to 24 years after the second dose.

The risk was also higher in this group after a second dose of the Moderna vaccine compared to the Pfizer-BioNTech vaccine.

In addition, among all age groups, the risk of myocarditis was higher after the second dose.

The study was published April 20, 2022, in JAMA CardiologyTrusted Source.

In this research, results from four separate studies — carried out in Denmark, Finland, Norway, and Sweden — were combined and reanalyzed in what’s known as a meta-analysis.

Inflammation occurs after vaccines for several viruses

A group of researchers from Singapore reviewed 22 studies that looked at the inflammation of the heart or the tissue around the heart — myocarditis or pericarditis — after vaccination.

These studies included several types of vaccines, such as COVID-19, smallpox, and seasonal influenza.

The rate of myocarditis or pericarditis was higher after smallpox vaccination compared to the COVID-19 vaccination. Heart inflammation was similar after receipt of the influenza vaccine and COVID-19 vaccine.

Studies looking at the COVID-19 vaccine found that the risk of heart inflammation was higher in males, people younger than 30 years old, after receiving an mRNA vaccine and after the second dose.

The study was published April 11, 2022, in The Lancet Respiratory MedicineTrusted Source.

Heart inflammation less common after booster dose

Researchers from the Centers for Disease Control and Prevention (CDC) reviewed around 3,400 reports of side effects experienced by 12- to 17-year-olds after a second dose or a booster dose of the Pfizer-BioNTech COVID-19 vaccine.

Over 2.8 million U.S. adolescents had received a booster dose of that vaccine at the time.

Most side effects were mild to moderate and short-lived. The frequency of local and systemic reactions was similar after the second dose and booster.

However, myocarditis was reported less frequently after the booster dose than the second dose.

All confirmed cases of myocarditis occurred in adolescent boys. Around 84 percent of these cases were hospitalized; no deaths were reported.

The study was published on March 4, 2022, in the CDC’s Morbidity and Mortality Weekly Report (MMWR)Trusted Source.

An earlier study by CDC researchers also found that heart inflammation was highest after the second dose and among males 12 to 24 years old.

Researchers examined data from the Vaccine Adverse Event Reporting System (VAERS) for the period December 2020 through August 2021.

Among 192 million Americans who received an mRNA COVID-19 vaccine during that time, around 1900 cases of myocarditis were reported to VAERS. Around 1600 of those met the strict definition of myocarditis.

The results were published January 25 in JAMATrusted Source.

Young males at highest risk of heart inflammation

In a study published Oct. 4, 2021, in JAMA Internal MedicineTrusted Source, researchers examined the electronic health records of over 2.3 million Kaiser Permanente Southern California members ages 18 and older who received at least one dose of the Pfizer-BioNTech or Moderna-NIAID vaccine between December 2020 and July 2021.

They identified 13 cases of myocarditis after the second dose — a rate of 5.8 cases per million second doses given.

Two cases occurred after the first dose, making for a much lower rate of 0.8 cases per million first doses.

“[This study] supports that this is a real phenomenon,” said Dr. Ira Taub, a pediatric cardiologist at Akron Children’s Hospital, who was not involved in the research. “The risk, though, is very, very small.”

All 15 cases of myocarditis identified by researchers occurred in men between 20 and 32 years old, with an average age of 25. None of the men had a history of heart problems.

About half had received the Pfizer-BioNTech vaccine, with the other half receiving the Moderna-NIAID vaccine.

All but one of the men reported chest pain between 1 and 5 days after vaccination.

The men were all hospitalized, but their symptoms improved with conservative treatment. None of them were admitted to the ICU or readmitted after being released from the hospital.

This study included a diverse population: 37.8 percent were Hispanic, 31.2 percent white, 14.3 percent Asian, and 6.7 percent Black. This helps generalize the results to the country as a whole.

Researchers also compared the risk of myocarditis after vaccination to the risk of this condition in people who were unvaccinated.

Myocarditis can also be caused by viral and bacterial infections, including COVID-19.

The risk of heart inflammation after the second dose was 2.7 times higher than the risk in a similar group of unvaccinated people.

Dr. Brian Kolski, director of the Structural Heart Disease Program at Providence St. Joseph Hospital in Orange County, California, said that there are limitations to the study. For example, it’s an observational study rather than a randomized trial, and there was a short follow-up time.

But he said that the results fit with other data on myocarditis after COVID-19 vaccination.

“There’s nothing in this study that suggests we’re missing an epidemic of young males who are having problems with the vaccine,” he said.

Another limitation of the study is that it only included people 18 years and older. Myocarditis can also occur in younger people after vaccination.

Still, “if they’d included a pediatric population, the study would have shown substantially the same thing,” said Taub. “We are not seeing an avalanche of pediatric myocarditis cases as a result of vaccination.”

As with adults, children, and adolescents who develop myocarditis after vaccination tend to recover quickly.

“Out of the children we’ve seen [at my institution], a couple needed to be hospitalized,” he said. “But everyone was discharged within a few days, no one was re-hospitalized, and all of their [heart] function was normal.”

Heart inflammation more common after COVID-19

Experts say the benefits of the vaccines still outweigh the rare risk of myocarditis, especially when compared to the risks of coronavirus infection.

In an Israeli study published in Sept. 2021, researchers examined the electronic health records of over 2 million people.

They found an additional 2.7 cases of myocarditis for every 100,000 people vaccinated with an mRNA COVID-19 vaccine.

But the risk of myocarditis after COVID-19 was higher, resulting in an extra 11 cases for every 100,000 people who had the infection.

This study didn’t take into account younger males specifically.

But the CDC estimatedTrusted Source in June 2021 that there would be 56 to 69 cases of myocarditis for every million 12-to-17-year-old males who received the second dose.

However, vaccination among this age group would prevent an estimated 5,700 cases of COVID-19, 215 hospitalizations, and two deaths.

Taub says that people should keep in mind that children and adolescents who develop myocarditis after coronavirus infection can get very sick.

However, “if they are treated, they bounce back pretty quickly,” he said. “We’re seeing kids in the clinic 6 months, 8 months, sometimes 10 months [after treatment], and for most of those kids, their [heart] function also eventually normalizes.”

Kolski said even with the small risk of myocarditis after vaccination, he’d still recommend that people get vaccinated against COVID-19.

However, given the greater risk of myocarditis in younger males after the second dose, two doses of the mRNA vaccine may not be appropriate for everyone.

“Maybe there’s a group of young, healthy males that only need one dose,” he said. “I think there’s some more nuanced conversations that have to occur.”

Both the United Kingdom and Hong Kong have opted to give certain adolescents a single dose of the mRNA vaccine. This provides them with some protection against COVID-19 but with a lower risk of myocarditis.

Is It Safe to Get the COVID-19 Vaccine If You Have Botox?

Vaccine safety

Botox and filler safety

Is this new?

Takeaway

If you have or are considering Botox or dermal fillers, you may have some extra questions about the COVID-19 vaccine. These questions are most likely the result of a side effect reported specifically from the Moderna vaccine.

During the phase 3 trial for the Moderna vaccine, 15,184 trial participants were given the vaccine. Out of those participants, three subjects who had had dermal fillers experienced mild facial swelling within 2 days of their vaccine dose.

Two of the subjects experienced swelling in the general area of their face, while one experienced lip swelling. None of the subjects with dermal fillers who were given the placebo experienced this side effect. The swelling went away completely with treatment at home for all three participants.

Before we go further, remember that Botox and dermal fillers are not the same things. Botox is an injectable muscle relaxer, while dermal fillers are synthetic materials meant to add volume and structure to your face. The people in the Moderna vaccine trial had dermal fillers.

Is it safe to get the vaccine?

Based on what we know so far, doctors still strongly recommend everyone who can get the COVID-19 vaccine should do so. A history of getting Botox and dermal fillers is not considered a reason to opt out. The protection offered from the vaccine is still believed to far outweigh the slight risk of swelling for people with dermal fillers.

The American Academy of Plastic Surgeons says that people with dermal fillers should not be discouraged from getting the COVID-19 vaccine. That’s because these side effects are considered rare. Even in the cases where these side effects were reported, they resolved quickly and didn’t have long-term health complications.

With that being said, the Moderna trial cases are not the only examples of swelling associated with dermal fillers and the COVID-19 vaccine.

A studyTrusted Source published in February 2021 mentions isolated, rare cases of swelling that seemed to have occurred in connection to the Moderna vaccine as well as the Pfizer vaccine. The study theorizes that this is the result of how the unique spike proteins in COVID-19 behave within your body.

These case studies let us know that these side effects are possible, but not at all likely. All of the cases of swelling were connected to dermal fillers that contained hyaluronic acid, and each of them resolved on their own, just like the Moderna trial participants.

Finally, keep in mind that contracting the coronavirus itself has been connected to facial swelling in people with dermal fillers in at least one caseTrusted Source. You may choose to avoid the COVID-19 vaccine because of its connection to swelling side effects, but that would mean that you are more vulnerable to contracting the virus, which can carry the same rare side effect.

Is it safe to get Botox or fillers after the vaccine?

There is no official guideline that recommends avoiding fillers or Botox after your COVID-19 vaccine.

That doesn’t mean that we won’t find out more about this in the future. There may be clearer guidelines to come from plastic surgeons and dermatologists about when you should get fillers or Botox after the COVID-19 vaccine.

For now, you can play it safe and wait until the vaccine has taken full effect until you get your next round of dermal fillers or Botox. It takes about 2 weeks after your second dose of the Pfizer or Moderna vaccines in order for the vaccine to take its full effect.

Is this a new phenomenon?

This is not the first time that a link between dermal fillers, exposure to a virus, and symptoms of temporary facial swelling have been linked.

During the Moderna trial, the same participant with dermal fillers who experienced swelling in the lip area reported that they had experienced a similar reaction after getting the flu shot. In the past, people receiving other types of vaccines were seen to have an increased riskTrusted Source of swelling side effects from dermal fillers. This has to do with how these vaccines activate your immune system.

A 2019Trusted Source paper noted increasing evidence that showed people who recently had the flu had a higher risk of delayed side effects, including swelling, from dermal fillers that contain hyaluronic acid. It’s possible that vaccines and recent virus exposure can cause your immune system to see the fillers as a pathogen, triggering an attack response on the filler material from your T cells.

Finally, it’s important to remember that temporary facial swelling is not an uncommon reaction for people that have had any type of fillers.

The bottom line

There have been some reports of people with dermal fillers experiencing facial swelling as a side effect of the Pfizer and Moderna COVID-19 vaccines. So far, reports of this side effect are extremely rare, and they are not long term. As of now, doctors and medical experts emphasize that the low risk of temporary swelling is far outweighed by the benefits of protection from COVID-19 vaccines.

Before you get your COVID-19 vaccine, speak to a medical professional about any concerns or questions that you have. Your primary physician should be able to evaluate your health history and give you the most up-to-date information on how the COVID-19 vaccines may affect you.

什么是技术？

自我传播的疫苗--也被称为称为可传播或自我繁殖的疫苗

--是在基因上设计成随着人群移动在人群中流动，以此方式在人群中传播，就像传染性疾病。但它们并不导致疾病，而是赋予保护。

我们的愿景是，在目标人群中，少数的一小部分人可以被接种疫苗，然后，疫苗菌株将在人群中循环流动，在人群中循环，就像一个致病病毒。这些疫苗可以极大地提高在人类或动物中的覆盖率，而不需要对每个人进行接种。这项技术目前主要针对的是主要针对动物群体。

因为大多数传染病是人畜共患的。控制动物种群中的疾病也将减少对人类的风险。有2种主要类型的自我传播的疫苗。重组载体疫苗和活病毒疫苗。重组载体疫苗结合了病原性病毒的元素，从而诱发免疫力（去除导致疾病的部分）和一个可传播的病毒载体。巨细胞病毒是一种候选载体。重组疫苗的候选载体，因为它具有高度的物种特异性和中等程度的传播。活的病毒疫苗是减活的，这意味着疫苗病毒的致病性远远低于野生型和疫苗的致病性比野生型的要低得多，并且与口服脊髓灰质炎疫苗或减毒活疫苗相似。因为，这些疫苗有时可以

在人与人之间传播。尽管在遗传学基因工程方面存在着巨大的技术挑战，但合成生物学工具，如CRISPR/Cas9等合成生物学工具可能会帮助研究人员在未来几年内克服这些障碍。

未来几年，合成生物学工具，如CRISPR/Cas9，有可能帮助研究人员克服这些障碍。

自我传播疫苗已经被用于保护野生兔子免受肌瘤病和控制啮齿类动物中的 "Sin Nombre "病毒。其他工作是针对猩猩和蝙蝠的埃博拉病毒，老鼠的拉萨病毒，以及獾的牛结核病。

自我传播的疫苗能解决什么问题？

最实际和最有用的应用，自传播疫苗将是控制疾病在野生动物种群中的疾病传播（也被称为 "动物传播"）。一种疫苗将被对少数选择的动物，目标人群中的热点地区群体，包括非人类灵长类动物。蝙蝠或啮齿动物。然后，该疫苗将在目标人群中传播，从而消除了对每只动物都接种疫苗。成功的动物中的疾病控制、群体中的疾病控制可以限制感染的动物，从而减少该疾病蔓延到人类身上的机会。

因此，在人类爆发疾病之前，就能阻止疾病的爆发，在它们出现之前就阻止人类的爆发，样一种战略将减少爆发的总体数量，但它不能阻断疫情，一旦它在人类中建立起来，出现严重的公共卫生威胁时，我传播的疫苗有可能被用来广泛接种人类人口。就像前面的办法一样，只有少量的疫苗的数量，就像在动物身上采取的方法一样，只需要少量的接种者，就可以为更多的易感人群提供保护。保护更多的易感人群。从而消除了需要进行大规模的疫苗接种

包括PODs在内的大规模接种行动。